96. Crohn disease
2,209 clinical trials,   1,276 drugs   (DrugBank: 240 drugs),   166 drug target genes,   210 drug target pathways

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03943446
(ClinicalTrials.gov)
August 4, 20207/5/2019TAK-018 for Prevention of the Recurrence of Postoperative Crohn's Disease (CD)A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn's Disease RecurrenceCrohn DiseaseDrug: TAK-018;Drug: TAK-018 PlaceboMillennium Pharmaceuticals, Inc.NULLRecruiting18 YearsN/AAll96Phase 2United States;Austria;France;Germany;United Kingdom;Netherlands
2EUCTR2019-000886-19-AT
(EUCTR)
06/05/202006/09/2019A study to evaluate the effects of TAK-018 on recurrence of Crohn’s Disease patients after bowel resectionA Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn’s Disease Recurrence Crohn’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: TAK-018
INN or Proposed INN: sibofimloc
Other descriptive name: EB8018
Product Code: TAK-018
INN or Proposed INN: sibofimloc
Other descriptive name: EB8018
Millennium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
96Phase 2United States;France;Austria;Netherlands;Germany;United Kingdom
3EUCTR2019-000886-19-NL
(EUCTR)
06/03/202017/09/2019A study to evaluate the effects of TAK-018 on recurrence of Crohn’s Disease patients after bowel resectionA Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn’s Disease Recurrence Crohn’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: TAK-018
INN or Proposed INN: sibofimloc
Other descriptive name: EB8018
Product Code: TAK-018
INN or Proposed INN: sibofimloc
Other descriptive name: EB8018
Millennium Pharmaceuticals, Inc (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
96Phase 2United States;France;Austria;Germany;Netherlands;United Kingdom
4EUCTR2019-000886-19-FR
(EUCTR)
20/01/202026/07/2019A study to evaluate the effects of TAK-018 on recurrence of Crohn’s Disease patients after bowel resectionA Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn’s Disease Recurrence Crohn’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Millennium Pharmaceuticals, Inc (a wholly owned subsidiaryNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
75Phase 2United States;France;Germany;United Kingdom
5EUCTR2019-000886-19-DE
(EUCTR)
26/11/201929/07/2019A study to evaluate the effects of TAK-018 on recurrence of Crohn’s Disease patients after bowel resectionA Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn’s Disease Recurrence Crohn’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: TAK-018
INN or Proposed INN: sibofimloc
Other descriptive name: EB8018
Product Code: TAK-018
INN or Proposed INN: sibofimloc
Other descriptive name: EB8018
Millennium Pharmaceuticals, Inc (A wholly owned subsidiary of Takeda Pharmaceutical Company Limited)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
96Phase 2United States;France;Austria;Netherlands;Germany;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2019-000886-19-GB
(EUCTR)
06/11/201929/07/2019A study to evaluate the effects of TAK-018 on recurrence of Crohn’s Disease patients after bowel resectionA Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for the Prevention of Postoperative Crohn’s Disease Recurrence - TAK-018 for Prevention of the Recurrence of Postoperative Crohn’s Disease Crohn’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: TAK-018
INN or Proposed INN: sibofimloc
Other descriptive name: EB8018
Product Code: TAK-018
INN or Proposed INN: sibofimloc
Other descriptive name: EB8018
Millennium Pharmaceuticals, Inc (a wholly owned subsidiaryNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
96Phase 2United States;France;Austria;Netherlands;Germany;United Kingdom